Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Reuters
2025.08.29 12:03
portai
I'm PortAI, I can summarize articles.

Esperion Therapeutics Inc :ESPERION’S BEMPEDOIC ACID RECEIVES LEVEL 1A RECOMMENDATION IN UPDATED ESC/EAS GUIDELINES FOR MANAGEMENT OF DYSLIPIDAEMIASESPERION THERAPEUTICS INC - BEMPEDOIC ACID RECOMMENDED FOR PATIENTS UNABLE TO TAKE STATIN THERAPY TO ACHIEVE LDL-C GOAL. CLASS I, LEVEL B

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.